Cantor Fitzgerald Initiates Coverage on Intercept Pharmaceuticals Inc to Sell

Cantor Fitzgerald Initiates Coverage on Intercept Pharmaceuticals Inc(NASDAQ:ICPT). The shares have been rated Sell. The rating by Cantor Fitzgerald was issued on Jul 6, 2016.

In a different note, On May 31, 2016, Cowen & Company said it Maintains its rating on Intercept Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $212.00 per share. The shares have been rated ‘Outperform’ by the firm. On May 31, 2016, JMP Securities said it Maintains its rating on Intercept Pharmaceuticals Inc. The shares have been rated ‘Market Outperform’ by the firm. On May 31, 2016, Morgan Stanley said it Maintains its rating on Intercept Pharmaceuticals Inc. The shares have been rated ‘Underweight’ by the firm. On May 31, 2016, Goldman Sachs said it Maintains its rating on Intercept Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $114.00 per share. The shares have been rated ‘Neutral’ by the firm. On Apr 8, 2016, Morgan Stanley said it Downgrades its rating on Intercept Pharmaceuticals Inc. In the research note, the firm Lowers the price-target to $100.00 per share. The shares have been rated ‘Underperform’ by the firm.

Intercept Pharmaceuticals Inc (ICPT) remained unchanged at the close of Monday session. Even as the volume increased to 5,04,475 ,the shares failed to make any impression and ended at 0 points or 0.00% at $151.73. The trading session commenced at $152.25 and the stock hit a high of $155.01 and touched $148.069 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $285 and the 52-week low is $89.76. The company has a market cap of $3,732 M and has approximately 2,45,95,270 outstanding shares.

Intercept Pharmaceuticals Inc(ICPT) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $445.00K. Analysts had an estimated revenue of $860.00K. Earnings per share were $-5.17. Analysts had estimated an EPS of $-3.60.

Several Insider Transactions has been reported to the SEC. On May 26, 2016, Lisa Bright (officer ) sold 251 shares at $137.50 per share price.Also, On May 4, 2016, Rachel Mcminn (Chief Strategy Officer) sold 130 shares at $147.49 per share price.On Apr 7, 2016, Mark Pruzanski (CEO & President) sold 708 shares at $130.76 per share price, according to the Form-4 filing with the securities and exchange commission.

Intercept Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate obeticholic acid (OCA) is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *